glp-1 drug shortages As Shortage Ends, Why Will Patients Pay More? FDA says that the GLP-1

Rapid changes without a maintenance plan can make long-term results harder to sustain

Adjuvant durvalumab was initiated in 73.6% of resected cases, with most patients remaining on treatment at data cutoff

Looking forward, the horizon seems promising for GLP-1 agonists, with new formulations and combination therapies under investigation

Payers and insurers are increasingly implementing restrictive coverage policies, such as limiting patient eligibility criteria, reducing prescription durations from 90 to 30 days, and favoring single-drug formularies to contain escalating costs

In trials and real-world experience, people have used GLP-1 medications safely for many years

A major role for VCAM-1, but not ICAM-1, in early atherosclerosis